SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

June 18, 2012 07:00 ET

Implant Sciences Adds Top Industry Executive and Former TSA Security Director as General Manager for the Americas

Company Continues to Strengthen Team With High Powered Industry Professionals

WILMINGTON, MA--(Marketwire - Jun 18, 2012) - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has attracted a top-performing sales leader in the explosives trace detection (ETD) industry. Todd Swearingen has been appointed General Manager for the Americas. He will oversee the federal and state sales channels in the Americas with focus on the aviation security markets, leading sales for the Company's Quantum Sniffer™ QS-B220 desktop explosives and drugs trace detector, which is currently undergoing U.S. Transportation Security Administration (TSA) qualification testing for air cargo screening.

Mr. Swearingen comes to Implant Sciences from The SAFRAN Group's Morpho Detection, formerly GE Homeland Security, where he was Director of Aviation Security for North America. He managed the Company's top two clients and was responsible for relationships with key stakeholders in US/Canadian governments, airlines, airports and industry leaders. Previously, he was Assistant Federal Security Director with the U.S. Department of Homeland Security's TSA at Dallas-Fort Worth International Airport, where he managed screening operations for over 1,200 Transportation Security Officers and the implementation of security technology, to include managing the largest state of the art in-line baggage system. Mr. Swearingen has also served as Senior Advisor to the TSA Administrator and served as a director within the U.S. Department of Labor. He began his career in active duty with the United States Coast Guard where he was an Analyst to the Commandant. Mr. Swearingen received his Business Management Degree in 1991 from Brown Mackie College in Kansas.

"Implant Sciences' technology, products, and the team they have assembled create an opportunity which I am very pleased to join," added Swearingen. "I look forward to playing a key role in presenting and implementing the Company's products which can better serve our nation's security needs through superior detection without the use of radioactive materials."

"We welcome Todd as the latest in a series of very talented industry participants who have left some of the largest players in the homeland security market to join our efforts here at Implant Sciences," stated Implant Sciences President and CEO Glenn D. Bolduc. "Todd brings a unique 360-degree view of the aviation security industry to the Company. His expert knowledge of security screening and solid relationships with TSA are strong assets for Implant Sciences as we move through the TSA qualification process with our QS-B220."

About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 benchtop explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact